Cardiac hypertrophy is enhanced in PPAR -/- mice in response to chronic pressure overload
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
AIMS: Peroxisome proliferator-activated receptor-alpha (PPARalpha) is a nuclear receptor regulating cardiac metabolism that also has anti-inflammatory properties. Since the activation of inflammatory signalling pathways is considered to be important in cardiac hypertrophy and fibrosis, it is anticipated that PPARalpha modulates cardiac remodelling. Accordingly, in this study the hypothesis was tested that the absence of PPARalpha aggravates the cardiac hypertrophic response to pressure overload. METHODS AND RESULTS: Male PPARalpha-/- and wild-type mice were subjected to transverse aortic constriction (TAC) for 28 days. TAC resulted in a more pronounced increase in ventricular weight and left ventricular (LV) wall thickness in PPARalpha-/- than in wild-type mice. Compared with sham-operated mice, TAC did not affect cardiac function in wild-type mice, but significantly depressed LV ejection fraction and LV contractility in PPARalpha-/- mice. Moreover, after TAC mRNA levels of hypertrophic (atrial natriuretic factor, alpha-skeletal actin), fibrotic (collagen 1, matrix metalloproteinase-2), and inflammatory (interleukin-6, tumour necrosis factor-alpha, cyclo-oxygenase-2) marker genes were higher in PPARalpha-/- than in wild-type mice. The mRNA levels of genes involved in fatty acid metabolism (long-chain acyl-CoA synthetase, hydroxyacyl-CoA dehydrogenase) were decreased in PPARalpha-/- mice, but were not further compromised by TAC. CONCLUSION: The present findings show that the absence of PPARalpha results in a more pronounced hypertrophic growth response and cardiac dysfunction that are associated with an enhanced expression of markers of inflammation and extracellular matrix remodelling. These findings indicate that PPARalpha exerts salutary effects during cardiac hypertrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Self-citationWatanabe, K., Fujii, H., Takahashi, T., Kodama, M., Aizawa, Y., Ohta, Y., Ono, T., Hasegawa, G., Naito, M., Nakajima, T., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000248200 · Cited by 314
PPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance
Guerre-Millo, M., Rouault, C., Poulain, P., André, J., Poitout, V., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Reach, G., & Staels, B. (2001) · Diabetes · doi:10.2337/diabetes.50.12.2809 · Cited by 241
Self-citationDiep, Q. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2003.11.004 · Cited by 165 · cited 3×
“The beneficial effect of PPARa activation on LV remodelling has also been attributed to the interference of PPARa with pro-inflammatory pathways converging on activator protein-1 (AP-1) and nuclear factor-kB (NF-kB), which are activated during hypertrophy.(14,36) PPARa activation was Figure 4 Continued.”
BackgroundPORTER, K., TURNER, N., OREGAN, D., & BALL, S. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.07.020 · Cited by 123
Cited by
Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.005 · Cited by 894
Lopaschuk, G. D., & Jaswal, J. S. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181e74a14 · Cited by 636
Jaswal, J. S., Keung, W., Wang, W., Ussher, J. R., & Lopaschuk, G. D. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.015 · Cited by 400
Kwong, J. Q., Lu, X., Correll, R. N., Schwanekamp, J. A., Vagnozzi, R. J., Sargent, M. A., York, A. J., Zhang, J., Bers, D. M., & Molkentin, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.002 · Cited by 359
SIRT3 regulates progression and development of diseases of aging
McDonnell, E., Peterson, B. S., Bomze, H. M., & Hirschey, M. D. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.06.001 · Cited by 217
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript the heart relies on FAO for most of its energy production, several mouse models of deficient lipid oxidation develop cardiac hypertrophy, including mice deficient in SIRT3, AMPactivated protein kinase (AMPK) [68], peroxisome proliferator-a…”
Metadata
- Authors
- Smeets, P. J. H., Teunissen, B. E. J., Willemsen, P. H. M., van Nieuwenhoven, F. A., Brouns, A. E., Janssen, B. J. A., Cleutjens, J. P. M., Staels, B., van der Vusse, G. J., & van Bilsen, M.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01-10
- Volume
- 78
- Issue
- 1
- Pages
- 79-89
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2062887672
- Cited by
- 126
- References
- 5
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiac hypertrophy is enhanced in PPAR -/- mice in response to chronic pressure overload. https://app.cochat.ai/papers/10.1093/cvr/cvn001
- The paper
- Smeets, P. J. H., Teunissen, B. E. J., Willemsen, P. H. M., van Nieuwenhoven, F. A., Brouns, A. E., Janssen, B. J. A., Cleutjens, J. P. M., Staels, B., van der Vusse, G. J., & van Bilsen, M. (2008). Cardiac hypertrophy is enhanced in PPAR -/- mice in response to chronic pressure overload. Cardiovascular Research. https://doi.org/10.1093/cvr/cvn001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.